Snowball logo
logo
CLCS_logo

Cell Source Inc

CLCS • PINK
$0.426-$0.1039  (19.61%)
Estimate
EPS
-0.07
Beta
-201.637
About the company
Ticker
CLCS
ISIN
US15114L1044
Country
United States of America
Sector (GICS)
Healthcare
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.

Frequently asked questions

What sector does Cell Source Inc (CLCS) operate in?

Cell Source Inc belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Cell Source Inc (CLCS) current stock price?

As of the latest data, Cell Source Inc stock price is $0.43, with a previous close of $0.53. Cell Source Inc lost -$0.10 in the last trading session, representing a -19.61% loss.

What is Cell Source Inc (CLCS) current market capitalization?

Cell Source Inc market cap is approximately 28.94 million.

What is Cell Source Inc (CLCS) Earnings Per Share (EPS)?

The trailing EPS is -$0.07.

Does Cell Source Inc (CLCS) pay dividends?

No. Cell Source Inc does not pay a dividend.

What is Cell Source Inc (CLCS) beta (volatility) score?

Cell Source Inc has a beta of -201.637, indicating lower volatility than the overall market.